Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Overview of attention for article published in Blood, August 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#1 of 47,250)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 174 news outlets
blogs: 3 blogs
policy: 4 policy sources
twitter: 39 X users

patent: 28 patents
wikipedia: 1 Wikipedia page
guideline: 5 clinical guideline sources

Readers on

mendeley: 1141 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 3 posts from 3 blogs.

#NephMadness 2025: CAR-T for Kidney Disease Region

AJKD Blog, 01 Mar 2025

Submit your picks! | @NephMadness | @nephmadness.bsky.social | NephMadness…

Medicina: Novartis riceve l’approvazione della Commissione Europea per la sua terapia cellulare CAR-T

Meteo Web, 27 Aug 2018

Novartis ha annunciato oggi che la Commissione Europea (CE) ha approvato Kymriah (tisagenlecleucel, noto in precedenza come…

Analysis reveals poor outcomes in refractory DLBCL

HematologyTimes, 12 Aug 2017

Micrograph showing DLBCLResults from the SCHOLAR-1 study revealed poor outcomes in patients with refractory diffuse large B-cell…

This page shows the most recent blog posts that mention this research output. Click here to find out how to access more activity.